FIELD: medicine.
SUBSTANCE: invention relates to medicine and represents a method of treating hematologic malignant diseases, which includes the introduction to a subject of a therapeutically effective quantity of an Aurora kinase inhibitor simultaneously or successively with an anti-CD20 antibody, where the Aurora kinase inhibitor represents 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or its pharmaceutically acceptable salt and where the anti-CD20 antibody represents rituximab.
EFFECT: invention provides more efficient treatment in comparison with monotherapy.
8 cl, 4 ex, 27 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| TRICYCLIC DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND METHOD OF INHIBITION OF VASOPRESSINE | 1994 |
|
RU2149160C1 |
| METHOD OF PRODUCING PYRIMIDO-2-BENZASIPINES OR THEIR PHARMACEUTICALLY COMPATIBLE ACID-ADDITIVE SALTS (VERSIONS) | 0 |
|
SU1181547A3 |
| CONDENSED AZEPINE DERIVATIVES AS ANTIDIUTETIC AGENTS | 2001 |
|
RU2269517C2 |
| (3-CYCLOALKYL-2, 3, 4, 5 - TETRAHYDRO-1H-BENZO [d] AZEPIN-7-YLOXY) DERIVATIVES, USE THEREOF FOR INHIBITING H3 RECEPTORS, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD | 2003 |
|
RU2388752C2 |
| 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS LEUCINE-RICH REPEAT KINASE 2 (LRRK2) MODULATORS FOR TREATMENT OF PARKINSON'S DISEASE | 2012 |
|
RU2661197C2 |
| SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR TREATING VESTIBULAR DISORDERS | 2009 |
|
RU2589846C2 |
| ANTIVIRAL REMEDIES FOR TREATMENT AND PREVENTION OF HIV INFECTION | 2021 |
|
RU2780103C1 |
| ANTIVIRAL REMEDIES FOR TREATMENT AND PREVENTION OF HIV INFECTION | 2020 |
|
RU2780101C2 |
| PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2013 |
|
RU2623221C2 |
| IMIDAZO[1,5-a]PYRIMIDO[5,4-d][1]BENZAZEPINE DERIVATIVES AS MODULATORS OF GABA A RECEPTOR | 2002 |
|
RU2287531C2 |
